How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Description:
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Sponsor:
Telix PharmaceuticalsContacts:
Kavita Vadaliglobal-clinicaltrials@telixpharma.com
+61 3 9093 3808
Government Study Link:
NCT05563272 - Click here to see study onClinicalTrials.gov
Inclusion
- Histologically or cytologically proven solid tumors
- Male or female >= 18 years old
- At least one non-CNS, measurable target lesion per RECIST 1.1 documented at conventional imaging within 30 days prior
Exclusion
- Previous administration of any radionuclide within 10 half-lives prior to administration of 89Zr-girentuximab
- Exposure to any antineoplastic treatment within 14 days from planned administration
- Exposure to any CAIX-targeting compound in the last 3 months
Patient Education
Patient Education Not Yet Provided
Locations
United States 🇺🇸
University Hospitals Of Cleveland
Cleveland, Ohio 44106, United States
Austin Radiological Association
Texas, United States
Carilion Clinic
Virginia, United States
Inland Imaging
Washington, United States
Biogenix Molecular LLC
Miami, Florida 33165, United States
